<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01036659</url>
  </required_header>
  <id_info>
    <org_study_id>ACE Induced Angioedema</org_study_id>
    <nct_id>NCT01036659</nct_id>
  </id_info>
  <brief_title>Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema</brief_title>
  <acronym>ACE</acronym>
  <official_title>Evaluation of Ecallantide for Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernstein, Jonathan A., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dyax Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bernstein, Jonathan A., M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a double-blind, randomized controlled trial comparing the
      safety and effectiveness of ecallantide to conventional therapy. A rescue cross-over design
      will be used such that patients failing to improve on standard therapy will additionally be
      treated with ecallantide. Therefore, a historical control cohort will be enrolled for
      analysis of secondary endpoints. In addition, since some patients treated with conventional
      therapy may improve rapidly and therefore not be eligible for inclusion in the study, the
      investigators will enroll these patients as an observational arm to enable the conduct of
      sensitivity analysis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective criteria that allow for discharge directly from the ED at or before 4 hours:(stable vital signs, no evidence of stridor, dysphagia or drooling, edema has regressed to or did not progress beyond Class I.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to meet objective discharge criteria, Physician assessment of angioedema improvement measured using the Symptom Complex Response Assessment at 2 hours post-treatment and 4 hours post-treatment.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Angioedema</condition>
  <arm_group>
    <arm_group_label>Ecallantide in conjunction with Conventional Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical Evaluation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ecallantide - Kallikrein inhibitor that blocks the production of bradykinin</intervention_name>
    <description>subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.</description>
    <arm_group_label>Ecallantide in conjunction with Conventional Therapy</arm_group_label>
    <arm_group_label>Conventional therapy and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females of any race or ethnicity 18 or older. The locations of the study
             will permit all racial and ethnic distribution in the study

          2. Must currently be on an ACE inhibitor

          3. Presenting with ACE induced angioedema within 12 hours after onset. This is to be
             documented in the source document and CRF

          4. All females of childbearing age must have a negative pregnancy test prior to
             administration of the study drug.

        Exclusion Criteria:

          1. Participation in another investigational study within 30 days prior to enrollment

          2. Patients who improve on conventional (standard of care) therapy

          3. Patients previously treated with ecallantide

          4. Hypersensitivity to ecallantide

          5. Pregnancy or breast feeding

          6. Other definable causes of angioedema (i.e., hereditary or acquired angioedema)

          7. Patients receiving C-1 inhibitor as prophylaxis

          8. Treatment requiring tranexamic acid, and epsilon-aminocaproic acid

          9. Receiving fresh frozen plasma within 3 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A. Bernstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Physicians, Division of Immunology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Moellman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Physicians, Department of Emergency Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jillian Picard, RN</last_name>
    <phone>513-558-0924</phone>
    <email>jillian.picard@uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah J. Holmes, RN</last_name>
    <phone>513-558-0924</phone>
    <email>sarah.holmes@uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jillian K Picard, RN, BSN</last_name>
      <phone>513-558-0924</phone>
      <email>Jillian.picard@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah J Holmes, RN, BSN</last_name>
      <phone>513-558-0924</phone>
      <email>Sarah.holmes@uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Moellman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jillian K Picard, RN, BSN</last_name>
      <phone>513-558-0924</phone>
      <email>Jillian.picard@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah J Holmes, RN, BSN</last_name>
      <phone>513-558-0924</phone>
      <email>Sarah.holmes@uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan A Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Physicians, Dpt of Internal Medicine, Division of Immunology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jillian Picard, RN</last_name>
      <phone>513-558-0924</phone>
      <email>jillian.picard@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah J. Holmes, RN</last_name>
      <phone>513-558-0924</phone>
      <email>sarah.holmes@uc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jonathan a. Bernstein, M.D.</name_title>
    <organization>UC Physicians, Department of Internal Medicine Division of Immunology</organization>
  </responsible_party>
  <keyword>acute angiotensin converting enzyme inhibitor angioedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kallikreins</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 30, 2014</submitted>
    <returned>November 4, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

